St. Jude Medical Inc. is "optimistic" that it will gain FDA approval for a patent foramen ovale closure device to prevent stroke in 2016, the firm's CEO Daniel Starks said on a July 22 earnings call.
The firm's Amplatzer PFO occlude was studied in the 980-patient RESPECT trial in which the device missed its primary intention-to-treat endpoint, but showed advantages compared to medication alone in preventing...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?